Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 27575024

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Oct
First author
Stintzing S

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Oct;17(10):e420. doi: 10.1016/S1470-2045(16)30440-5.
    note
    Source null
    related pmid
    27592806
    relationship
    Erratum in
  2. citation
    Lancet Oncol. 2016 Oct;17(10):1345-1347. doi: 10.1016/S1470-2045(16)30443-0.
    note
    Source null
    related pmid
    27733257
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2016 Nov;17(11):e479. doi: 10.1016/S1470-2045(16)30514-9.
    note
    Source null
    related pmid
    27819245
    relationship
    Erratum in
  4. citation
    Lancet Oncol. 2016 Dec;17(12):e515. doi: 10.1016/S1470-2045(16)30568-X.
    note
    Source null
    related pmid
    27924746
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2016 Dec;17(12):e516. doi: 10.1016/S1470-2045(16)30597-6.
    note
    Source null
    related pmid
    27924747
    relationship
    Comment in

Authors and identifiers

  1. name
    Stintzing S
    type
    Author
  2. name
    Modest DP
    type
    Author
  3. name
    Rossius L
    type
    Author
  4. name
    Lerch MM
    type
    Author
  5. name
    von Weikersthal LF
    type
    Author
  6. name
    Decker T
    type
    Author
  7. name
    Kiani A
    type
    Author
  8. name
    Vehling-Kaiser U
    type
    Author
  9. name
    Al-Batran SE
    type
    Author
  10. name
    Heintges T
    type
    Author
  11. name
    Lerchenmüller C
    type
    Author
  12. name
    Kahl C
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Stintzing S
    type
    Author
  2. name
    Modest DP
    type
    Author
  3. name
    Rossius L
    type
    Author
  4. name
    Lerch MM
    type
    Author
  5. name
    von Weikersthal LF
    type
    Author
  6. name
    Decker T
    type
    Author
  7. name
    Kiani A
    type
    Author
  8. name
    Vehling-Kaiser U
    type
    Author
  9. name
    Al-Batran SE
    type
    Author
  10. name
    Heintges T
    type
    Author
  11. name
    Lerchenmüller C
    type
    Author
  12. name
    Kahl C
    type
    Author
bibliography ids
  1. nci-bib-b4d98ee6948048bef3c037dc
book metadata
content sha256
d3306385cba9cbb766a177ebcd0441d4abc77a9f89c076bf2300feb2c637ee2e
document type
citation
dois
  1. 10.1016/S1470-2045(16)30269-8
electronic publication date
display
2016 Aug 27
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27575024
immutable id
pubmed:27575024@d3306385cba9cbb766a177ebcd0441d4abc77a9f89c076bf2300feb2c637ee2e
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1426-1434
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Oct;17(10):e420. doi: 10.1016/S1470-2045(16)30440-5.
    note
    Source null
    related pmid
    27592806
    relationship
    Erratum in
  2. citation
    Lancet Oncol. 2016 Oct;17(10):1345-1347. doi: 10.1016/S1470-2045(16)30443-0.
    note
    Source null
    related pmid
    27733257
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2016 Nov;17(11):e479. doi: 10.1016/S1470-2045(16)30514-9.
    note
    Source null
    related pmid
    27819245
    relationship
    Erratum in
  4. citation
    Lancet Oncol. 2016 Dec;17(12):e515. doi: 10.1016/S1470-2045(16)30568-X.
    note
    Source null
    related pmid
    27924746
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2016 Dec;17(12):e516. doi: 10.1016/S1470-2045(16)30597-6.
    note
    Source null
    related pmid
    27924747
    relationship
    Comment in
outcomes validated
false
pmid
27575024
provenance
batch id
d649bcb2d98dbbacd53c
provider
NCBI PubMed ESummary
record sha256
56b9160bb6be51c73d59bed9db6623e136f50730e7608c74dca33c4efb5d01cf
response sha256
26648a40f123f366675007f51cc29befd1f9a89273ca2da87c477c54d2d15d20
retrieved at
2026-09-09T23:47:20.761544+00:00
publication date
display
2016 Oct
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27575024/
title
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

Preserved source evidence · Independent clinical review pending · Not medical advice